Latest Research in CAR-T cell therapy research
48 research papers · 2026 median publication year
Top Research Topics in CAR-T cell therapy research
- CAR-T cell therapy research — 15 papers
- Immune Cell Function and Interaction — 10 papers
- Virus-based gene therapy research — 3 papers
- Monoclonal and Polyclonal Antibodies Research — 3 papers
- Cancer Immunotherapy and Biomarkers — 2 papers
- Immunotherapy and Immune Responses — 2 papers
- Acute Myeloid Leukemia Research — 2 papers
- Coagulation, Bradykinin, Polyphosphates, and Angioedema — 1 papers
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms — 1 papers
- HER2/EGFR in Cancer Research — 1 papers
Highest-Cited Papers
- A first-in-human, phase I/IIa trial of the T cell immunotherapy personalised tumour trained lymphocytes in patients with advanced colorectal cancer: Study protocol
- Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia
- Structural Foundation of CTLA-4 antibodies: Emerging Platforms for Next-generation Cancer Immunotherapy
- Subset-guided IL-15 expansion of NK cells amplifies antigen-specific CD4+ T cell immunity in melanoma
- An activation-biased 2B4 costimulatory domain enhances IFN-γ production and supports sustained cytotoxic activity in CD5-targeting CAR-NK92 cells
- Antibodies against HLA-E-VL9 enhance NK cell and CD8+ T cell cytotoxicity against tumor cells and HIV-infected CD4+ T cells.
- Bacterial RNA downregulates MHC-I in tumor cell lines, promoting NK response and delaying tumor growth
- Baseline IFN-γ-based natural killer cell activity is associated with ex vivo expansion capacity of autologous NK cells in patients with breast cancer
- Engineering strategies to address immune and delivery barriers in pancreatic ductal adenocarcinoma: a barrier-matched translational framework
- Brief Communication: LSD1 Inhibition Enhances Susceptibility of Primary AML Cells for NK Cell-Mediated Killing
- Resistance mechanisms and therapeutic strategies after menin inhibitor failure in acute myeloid leukemia
- Tumor-targeted IL-10 synergizes with IL-2 to enhance antitumor immunity while minimizing immune-related adverse events
- TCR-T cell therapy for advanced solid tumors: a critical review of the 2026 ASCO annual meeting data
- Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma
- TLR8 Stimulation Leads to Microenvironment Activation and Enhanced Antibody-Dependent Cellular Responses in CLL
- Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers
- Autologous Glypican-3–Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102
- A PRK-armed oncolytic adenovirus drives calreticulin exposure for dendritic cell licensing to prime antitumor CD8⁺ T cells and synergizes with anti-PD-1 or CAR-T therapy in colorectal cancer
- Key barriers in utilizing advanced T-cell engager strategies on solid tumors
- Emerging Biomarkers and Biotherapies for EBV-Associated Cancers